THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announces the addition of Fadi Braiteh, M.D., to its advisory board. Dr. Braiteh is a practicing oncologist with the Comprehensive Cancer Centers of Nevada, and a leading specialist on gastro-intestinal, digestive system and breast cancer oncology. He joins a board comprised of numerous nationally and internationally-recognized oncology and pathology experts.
After receiving his medical degree from Saint Joseph’s University in Beirut, Lebanon, Dr. Braiteh completed his internal medicine internship and residency at the Yale School of Medicine and three fellowships at the University of Texas M.D. Anderson Cancer Center—in medical oncology, phase I drug development and palliative care and symptom management. He has received numerous awards, including the 2009 Susan G. Komen Scholar-In-Training Award, the 2007 Jesse Jones Fellowship in Cancer Education Award, and the 2005 and 2006 ASCO Foundation Merit Awards.
“We are still mired in classifying cancers by what we can see in the optical microscope, an instrument invented 350 years ago. Modern tools have taught us that cancers are far more complex and diverse than they look, and in the current age of genomics, we now know the importance of analyzing cancer cells on a molecular level,” said Dr. Braiteh. “This is all the result of technological advances by companies like MolecularHealth that allow for each specific case and each patient to be treated individually, rather than as member of a subcategory. Next-generation sequencing, along with this in-depth analysis, make possible the identification of the molecular subtype of the cancer, and the ability choose adequate treatment and avoid unnecessary exposure to futile treatments.”
Lloyd Everson, M.D., chief executive officer of MolecularHealth, Inc. added, “We are fortunate to have built an incredibly strong advisory board that is helping to guide our company as we expand our TreatmentMAP™ sales efforts and reach within the molecular diagnostic market. Given Dr. Braiteh’s wealth of knowledge in oncology and cancer genetics, I know that he’ll be an asset to the board, and we look forward to working with him.”
MolecularHealth’s TreatmentMAP was commercially launched in April and is gaining traction with oncology practices and hospitals throughout the U.S. and Europe. Using a proprietary analytics engine to combine precision medicine with advanced data analysis, the offering guides physicians to the safest and most effective cancer treatment options for their patients. TreatmentMAP is accessible to all patients diagnosed with solid tumor cancer, regardless of where they live.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.